STAT3 and ovarian carcinoma: Since both siRNA-mediated and pharmacological STAT3 inhibition has been previously shown to reverse paclitaxel and cisplatin resistance in ovarian cancer cells (14, 15), we tested the reliance of Olaparib-resistant ovarian cancer cells on STAT3 signaling for survival.